Kate Haviland: Yes. So thank you for the question. Let me take the first part on the bolus. I think – and the point I can weigh in on the impact of Quad AI. I think from both perspective, the reason why we’re not saying that we don’t expect it because we designed the PIONEER study to evaluate long-term follow-up of the patients. And so in a product launch, when you see a bolus, it’s often because you’re switching patients off of clinical trials into commercial drug. And we believe the long-term experience of AYVAKIT treatment in these patients is critically important to the overall value as we continue to look at that impact over time. So we’re retaining patients within the PIONEER study for up to 5 years. So that is why we don’t expect a bolus coming out of clinical trials into commercial therapy. And Philina, do you want to talk about the – how you see the impact of Quad AI?
Philina Lee: Yes, sure. So I mean, I think, first and foremost, I want to also talk about the efforts that the team is doing to prepare for the launch and sort of feed towards the ultimate ramp upon approval as well. So as I mentioned, we’re hyper focused on three critical areas, the broader provider engagement, both within the existing prescriber base for AYVAKIT as well as that broader prescriber base. Future prescriber base, including allergists immunologists, we’re focused on activating patients and maintaining our strong patient access. And so among that, when we think about the importance of Quad AI, clearly, it will increase the awareness of AYVAKIT, especially among that allergists and immunologist community, awareness of AYVAKIT as well as the data.
As far as our teams focus as well, a couple of factors that we think will help with the ramp is that for many years, we have been engaging to increase disease awareness as well as diagnosis rates. And our team has been really honing and perfecting our skills with the advanced SM launch. So we know how to leverage advanced analytics and our field acumen to find patients. We know how to identify their providers, and we know how to engage these providers leveraging our deep disease state expertise. So we are confident as we think about that overall $1.5 billion peak opportunity, that we will ultimately be able to capture this opportunity.
Michael Ulz: Very helpful. Thank you.
Operator: Our next question comes from Reni Benjamin from JMP Securities. Your line is now open.
Reni Benjamin: Hey, guys. Thanks for taking the questions and congratulations on the quarter and outlook for 2023. Can you talk a little bit about how we should be thinking about the sales force and their switch to focus on allergists? Is this something that likely we’re going to have to increase as we get into the year and after approval, do you have a sense as to how many docs are currently aware of AYVA and ISM versus not as well?
Kate Haviland: Yes. Thank you, Ben, for the question. And I’ll turn it over to Philina to answer the question about the sales force. I think one of the great attributes of this launch for us is that it is really an extension of what we’ve been doing in SM, and it is still – it’s a specialty market. So it’s a market that we can certainly access with incremental growth in our field infrastructure. But Philina talk a little bit about how you’re thinking about that.
Philina Lee: Yeah, so as Kate mentioned, with – advanced SM provides a strong foundation, right? So the primary specialty focus historically for us has been hematology and oncology. But as we prepare for the ISM launch, we know that we’ll need to engage a broader provider and specialty base, including allergists. And so we’ve incrementally expanded our field force and strengthened our capabilities in allergy, immunology, as well as rare disease. And to your question on awareness, at this point, we’re in a very strong position with awareness of AYVAKIT among target prescribers of over 40%.
